Innoviva Q2 revenue rises 19% to $119.6 million; swings to $83.4 million net loss
Innoviva reported second-quarter 2026 results for the period ended June 30, 2026. Total revenue grew 19% from a year earlier, led by 46% growth in net product sales, but the company posted a net loss of $83.4 million, or $1.14 per basic share, compared with net income of $63.7 million a year earlier. The loss was driven mainly by unfavorable changes in the fair value of its equity and long-term investments, primarily from a lower share price of Armata Pharmaceuticals.
Key points
- Total revenue was $119.6 million, up from $100.3 million in the second quarter of 2025.
- Net product sales were $51.8 million, up 46%, with U.S. sales of $36.6 million.
- Net loss was $83.4 million, or $1.14 per basic share, versus net income of $63.7 million in the prior-year quarter.
- The company repurchased 1,403,247 shares for $31.4 million in the quarter under its $125 million program.
The filing
Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.